Food Effect, Efficacy and Safety of MKP10241 in Healthy and Obese Adult Participants, With and Without Diabetes

Exclusion Criteria

• •Clinically significant haematological findings at Screening.
• •Hepatic impairment including aspartate aminotransferase (AST), alanine transaminase (ALT), or alkaline phosphatase ≥1.5 times upper limit of normal (ULN), total bilirubin ≥2.0 times ULN, albumin ≤3.0 g/L, serum amylase or lipase ≥1.5 times ULN at Screening.
• •Renal impairment, such as creatinine ≥ULN, estimated glomerular filtration rate (eGFR) of ≤80 mL/minute/1.73m2 in adults, as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
• •Positive polymerase chain reaction (PCR) test for severe-acute-respiratory-syndrome-related coronavirus (SARS-CoV-2)
• •A history of non-febrile seizures.
• •Positive pregnancy test result at Screening or on admission to the CRU,
• •Any major surgery within 60 days prior to Screening, or planned major surgery during the study.
• •Any history of malignant disease excluding surgically resected skin and in-situ cervical squamous cell or basal cell carcinoma.
• •Suspected hypersensitivity to MKP10241 and any components of MKP10241 liquid suspension
• •Any other condition which makes the participant unsuitable for study participation as judged by the Investigator or designee.
• •Participant has any history or evidence of any clinically significant disease
• •Prior or planned (during study period) bariatric surgery (e.g. gastric bands, gastroplasty Roux-e-Y gastric bypass) or ileal resection.
• •Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-V) substance use disorders and alcohol abuse within 12 months prior to Screening and/or positive alcohol breath test at Screening or admission.
• •Positive result for drugs of abuse at Screening or admission.
• •Use of live attenuated vaccines within 14 days prior to dosing
• •The use of medications (other than paracetamol), including hormonal contraceptives
• •Receipt of any other investigational medicinal product within one month or five half-lives (whichever is longer) prior to dosing.
• •Clinically significant ECG findings: QTcF value ≥450 ms for males or ≥470 ms for females at Screening or Day -1
• •Participants with a mean systolic blood pressure \>140 mmHg, mean diastolic blood pressure \>90 mmHg at Screening.
• •Positive blood screen for human immunodeficiency virus antibody (HIV), hepatitis B surface antigen (HBsAg), syphilis, hepatitis C virus (HCV).
• •Change in body weight of ≥ 10% within 3 months prior to the Screening visit.
• •Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products, plasma) or acute loss of blood during the 30 days prior to Screening.
• •Part 3: Type 1 diabetes mellitus, maturity-onset diabetes of the young, or other forms of diabetes.